CAR T-cell therapies have demonstrated significant clinical success in the treatment of CD19+ hematological malignancies, with complete response rates reported for the majority of patients with acute lymphoblastic leukemias and follicular lymphoma [7, 26] [and American Society of Clinical Oncology, ASCO 2015]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.